C Haïoun Selected Research

Monoclonal Antibodies

1/2001

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

C Haïoun Research Topics

Disease

2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2001 - 12/2000
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2001
1	Neoplasms (Cancer) 01/2001
1	Pathologic Complete Response 01/2001

Drug/Important Bio-Agent (IBA)

1	Monoclonal AntibodiesIBA 01/2001
1	CD20 AntigensIBA 01/2001
1	Rituximab (Mabthera)FDA Link 01/2001

Therapy/Procedure

2	Therapeutics 01/2001 - 12/2000
1	Aftercare (After-Treatment) 01/2001
1	Stem Cell Transplantation 12/2000